30.770
Bearbeitungen
Änderungen
→Literatur
==Literatur==
==Literatur==
*Joanna Hellmuth "Can we trust The End of Alzheimer’s?", Lancet Neurol. 1.5.2021 doi: 10.1016/S1474-4422(20)30113-7, PMCID: PMC7377549 NIHMSID: NIHMS1608084 PMID: 32333896 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377549/
*Joanna Hellmuth "Can we trust The End of Alzheimer’s?", Lancet Neurol. 1.5.2021 doi: 10.1016/S1474-4422(20)30113-7, PMCID: PMC7377549 NIHMSID: NIHMS1608084 PMID: 32333896 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377549/
*Rammohan V Rao, Sharanya Kumar, Julie Gregory, Christine Coward, Sho Okada, William Lipa, Lance Kelly, Dale E Bredesen:
ReCODE: A Personalized, Targeted, Multi-Factorial Therapeutic Program for Reversal of Cognitive Decline, Biomedicines. 2021 Sept 29;9(10):1348. PMCID: PMC8533598 PMID: 34680464
*[https://clinicaltrials.gov/study/NCT03883633 Reversal of Cognitive Decline (ReCODE) Study (RECODE), ClinicalTrials.gov ID NCT03883633. Sponsor QuesGen
*[https://clinicaltrials.gov/study/NCT03883633 Reversal of Cognitive Decline (ReCODE) Study (RECODE), ClinicalTrials.gov ID NCT03883633. Sponsor QuesGen
*Timothy Daly, Ignacio Mastroleo, David Gorski, Stéphane Epelbaum: The ethics of innovation for Alzheimer’s disease: the risk of overstating evidence for metabolic enhancement protocols, Springer nature, 18.1.2021, Volume 41, S. 223–237
*Timothy Daly, Ignacio Mastroleo, David Gorski, Stéphane Epelbaum: The ethics of innovation for Alzheimer’s disease: the risk of overstating evidence for metabolic enhancement protocols, Springer nature, 18.1.2021, Volume 41, S. 223–237